ArticleMolecular oncology2018

Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.

Wenbin Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.